Contravisory Investment Management’s Royal Bank of Canada RY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$431K Buy
2,083
+30
+1% +$5.57K 0.08% 158
2026
Q1
$332K Sell
2,053
-126
-6% -$21.1K 0.07% 166
2025
Q4
$371K Buy
2,179
+9
+0.4% +$1.38K 0.07% 170
2025
Q3
$320K Buy
2,170
+129
+6% +$17.8K 0.06% 197
2025
Q2
$268K Buy
2,041
+85
+4% +$10.4K 0.05% 214
2025
Q1
$220K Buy
1,956
+73
+4% +$8.6K 0.05% 236
2024
Q4
$227K Buy
1,883
+40
+2% +$4.94K 0.05% 210
2024
Q3
$230K Buy
+1,843
New +$212K 0.05% 204
2023
Q2
Sell
-1,070
Closed -$102K 364
2023
Q1
$102K Buy
1,070
+93
+10% +$9.22K 0.03% 217
2022
Q4
$91.9K Sell
977
-3
-0.3% -$283 0.03% 222
2022
Q3
$88K Hold
980
0.03% 215
2022
Q2
$95K Sell
980
-11
-1% -$1.13K 0.03% 217
2022
Q1
$109K Hold
991
0.03% 215
2021
Q4
$105K Buy
991
+88
+10% +$9.13K 0.03% 212
2021
Q3
$90K Buy
+903
New +$92K 0.03% 212

Other funds holding RY

Contravisory Investment Management's RY Position: Q2 2026 in Review

Contravisory Investment Management increased its Royal Bank of Canada (RY) stake by 1.5% in Q2 2026, buying an estimated $5.57K and bringing the position to 2,083 shares worth $431K. The position accounts for 0.08% of the portfolio, ranked #158.

Contravisory Investment Management first reported a position in RY in Q3 2021 and has held it in 15 quarters since. 982 funds tracked by Wall St. Rank hold RY as of Q2 2026.

  • Contravisory Investment Management held 2,083 shares of Royal Bank of Canada worth $431K as of Q2 2026.
  • Contravisory Investment Management bought 30 Royal Bank of Canada shares in Q2 2026, an estimated $5.57K.
  • Royal Bank of Canada made up 0.08% of Contravisory Investment Management's portfolio in Q2 2026, its #158 holding.
  • Contravisory Investment Management first reported a position in Royal Bank of Canada in Q3 2021 and has held it in 15 quarters since.
  • 982 funds tracked by Wall St. Rank held Royal Bank of Canada as of Q2 2026.

Based on Contravisory Investment Management's 13F filing for Q2 2026, filed 9 Jul 2026.